| Wissenschaftl. Titel | A phase IIa, open-label, multicenter study of radiochemotherapy with isotoxic dose escalation and protective VEGF inhibition using bevacizumab in the treatment of patients with first diagnosis of IDH wild-type, MGMT unmethylated glioblastoma |
| Erkrankung |
Neuro:
Glioblastom (WHO Grad IV):
Erstlinie
|
| Molekularer Marker |
IDH1 wt MGMT Promotormethylierung neg. |
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (F) Weiterführende Informationen (NIH) |
erstellt 22.07.2024 Data entry IX CCP
geändert 26.07.2024 Data entry III CCP